Six brokerage firms covering Senseonics have issued recommendations over the past year, resulting in an average rating of Buy. Two analysts rate the shares as Strong Buy, three issue Buy opinions and one maintains a Hold. The consensus 12-month price target across these reports stands at $22.70, reflecting a range from $9.00 to $31.00. Notable recent actions include HC Wainwright raising its target to $18.50, Barclays lifting its target from $1.50 to $31.00 while reaffirming an Overweight rating, and TD Cowen adjusting its target downward from $25.00 to $15.00 yet maintaining a Buy stance.

Director Edelman Steven acquired 10,000 shares at an average cost of $6.55 in mid-November, increasing his holding by 15.5% to 74,708 shares. Director Douglas A. Roeder purchased 15,000 shares at $5.83 per share, boosting his position by 17.7% to 99,727 shares. CFO Frederick T. Sullivan added 5,415 shares at $5.88, representing a 3.6% rise in his stake. In total, insiders have acquired 30,415 shares over the last 90 days for approximately $185,000, bringing insider ownership to 3.6% of outstanding stock.

Twelve-point-three-six percent of Senseonics shares are held by institutional investors and hedge funds. Notable recent moves include Goldman Sachs increasing its position by 26.2% during Q1, adding 127,086 shares to reach 612,534 shares. Keynote Financial Services grew its stake by 1,120.2% in Q2, purchasing an additional 191,215 shares to hold 208,285 shares. Other new stakes were established by State of Wyoming in Q1 and CTC Alternative Strategies in Q1, while Geode Capital and Elite Life Management each boosted their holdings during Q2.

Headquartered in Germantown, Maryland and founded in 2011, Senseonics develops the Eversense continuous glucose monitoring (CGM) system, featuring a fully implantable sensor with up to 90-day wear in the U.S. and 180-day in Europe. The company maintains a strong liquidity profile, with a current ratio of 2.47 and a quick ratio of 2.38, alongside a debt-to-equity ratio of 59.17%. Despite an ongoing operating loss reflected in a negative P/E ratio, management emphasizes the sensor’s differentiated 90-day implant duration and long-term recurring revenue potential from sensor replacements.